VBL Therapeutics Overview
- Year Founded
-
2000
- Status
-
Acquired/Merged
- Employees
-
7
- Latest Deal Type
-
M&A
- Latest Deal Amount
-
$145M
- Investors
-
3
VBL Therapeutics General Information
Description
Vascular Biogenics Ltd is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of first-in-class treatments for cancer. The lead product candidate of the company is VB-111 which is a gene-based biologic which is being developed for solid tumor indications for recurrent glioblastoma, an aggressive form of brain cancer. The company is also engaged in conducting a program targeting anti-inflammatory diseases, based on the use of Lecinoxoid platform technology. The product brands of the company include VTS, Vascular Targeting Systems, Vbl, Vascular Biogenics And Vascular Therapeutics.
Contact Information
Website
www.vblrx.comCorporate Office
- 8 HaSatat Street
- Modiin 7178106
- Israel
Corporate Office
- 8 HaSatat Street
- Modiin 7178106
- Israel
VBL Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 12. Merger/Acquisition | 16-Oct-2023 | $145M | Completed | Generating Revenue | ||
| 11. Grant | 06-Oct-2021 | Completed | Generating Revenue | |||
| 10. 2PO | 13-Apr-2021 | Completed | Generating Revenue | |||
| 9. PIPE | 13-May-2020 | Completed | Generating Revenue | |||
| 8. Secondary Transaction - Open Market | Completed | Generating Revenue | ||||
| 7. PIPE | 13-May-2020 | Completed | Generating Revenue | |||
| 6. Secondary Transaction - Open Market | 11-Feb-2017 | Completed | Product Development | |||
| 5. 2PO | 07-Jun-2016 | Completed | Generating Revenue | |||
| 4. Secondary Transaction - Open Market | 11-Feb-2016 | $153M | Completed | Product Development | ||
| 3. IPO | 31-Jul-2014 | $40M | $153M | Completed | Product Development |
VBL Therapeutics Comparisons
Industry
Financing
Details
VBL Therapeutics Competitors (36)
One of VBL Therapeutics’s 36 competitors is Dynavax Technologies, a Formerly VC-backed company based in Emeryville, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Dynavax Technologies | Formerly VC-backed | Emeryville, CA | ||||
| VBI Vaccines | Corporation | Cambridge, MA | ||||
| Adaptimmune Therapeutics | Formerly VC-backed | Abingdon, United Kingdom | ||||
| Ayala Pharmaceuticals | Corporation | Wilmington, DE | ||||
| Amarantus BioScience Holdings | Formerly Accelerator/Incubator backed | New York, NY |
VBL Therapeutics Signals
VBL Therapeutics Former Investors (6)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| GlenRock Israel | Growth/Expansion | Minority | ||
| JJD Holdings | Corporation | Minority | ||
| Angel (individual) | Minority | |||
| Pitango Venture Capital | Venture Capital | Minority | ||
| Teva Pharmaceutical Industries | Corporation | Minority |
VBL Therapeutics Acquisitions (1)
VBL Therapeutics’s most recent deal was a Reverse Merger with Notable Labs for . The deal was made on 16-Oct-2023.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Notable Labs | 16-Oct-2023 | Reverse Merger | Drug Discovery |
VBL Therapeutics ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Commercial Services
Industry
Rank
Percentile
Business Support Services
Subindustry
Rank
Percentile
VBL Therapeutics FAQs
-
When was VBL Therapeutics founded?
VBL Therapeutics was founded in 2000.
-
Where is VBL Therapeutics headquartered?
VBL Therapeutics is headquartered in Modiin, Israel.
-
What is the size of VBL Therapeutics?
VBL Therapeutics has 7 total employees.
-
What industry is VBL Therapeutics in?
VBL Therapeutics’s primary industry is Drug Discovery.
-
Is VBL Therapeutics a private or public company?
VBL Therapeutics is a Private company.
-
What is the current valuation of VBL Therapeutics?
The current valuation of VBL Therapeutics is .
-
What is VBL Therapeutics’s current revenue?
The current revenue for VBL Therapeutics is .
-
How much funding has VBL Therapeutics raised over time?
VBL Therapeutics has raised $232M.
-
Who are VBL Therapeutics’s investors?
GlenRock Israel, JJD Holdings, , Pitango Venture Capital, and Teva Pharmaceutical Industries are 5 of 6 investors who have invested in VBL Therapeutics.
-
Who are VBL Therapeutics’s competitors?
Dynavax Technologies, VBI Vaccines, Adaptimmune Therapeutics, Ayala Pharmaceuticals, and Amarantus BioScience Holdings are some of the 36 competitors of VBL Therapeutics.
-
When was VBL Therapeutics acquired?
VBL Therapeutics was acquired on 16-Oct-2023.
-
Who acquired VBL Therapeutics?
VBL Therapeutics was acquired by Notable Labs.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process